Keymed and Lepu Biopharma have announced a global exclusive licensing agreement with AstraZeneca for…
Keymed Biosciences Inc. and Lepu Biopharma Co., Ltd jointly announce a global exclusive licence agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody…
Read More...
Read More...
